To access the full text documents, please follow this link: http://hdl.handle.net/2445/104296
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | Wedemeyer, Heiner |
dc.contributor.author | Forns, Xavier |
dc.contributor.author | Hézode, Christophe |
dc.contributor.author | Lee, Samuel S |
dc.contributor.author | Scalori, Astrid |
dc.contributor.author | Voulgari, Athina |
dc.contributor.author | Le Pogam, Sophie |
dc.contributor.author | Nájera, Isabel |
dc.contributor.author | Thommes, James A |
dc.date | 2016-11-30T13:22:45Z |
dc.date | 2016-11-30T13:22:45Z |
dc.date | 2016-01-11 |
dc.date | 2016-11-30T13:22:51Z |
dc.identifier.citation | 1932-6203 |
dc.identifier.citation | 664025 |
dc.identifier.uri | http://hdl.handle.net/2445/104296 |
dc.format | 22 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | Public Library of Science (PLoS) |
dc.relation | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0145409 |
dc.relation | PLoS One, 2016, vol. 11, num. 1, p. e0145409 |
dc.relation | https://doi.org/10.1371/journal.pone.0145409 |
dc.rights | cc-by (c) Wedemeyer, Heiner et al., 2016 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.subject | Hepatitis C |
dc.subject | Virus de l'hepatitis C |
dc.subject | Antiretrovirals |
dc.subject | Anèmia |
dc.subject | Cirrosi hepàtica |
dc.subject | Assaigs clínics |
dc.subject | Hepatitis C |
dc.subject | Hepatitis C virus |
dc.subject | Antiretroviral agents |
dc.subject | Anemia |
dc.subject | Hepatic cirrhosis |
dc.subject | Clinical trials |
dc.title | Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |